Tattersalls and Goffs Announce New Policies for Corticosteroids and Bronchodilators

Tattersalls and Goffs are to introduce new restrictions relating to the use of corticosteroids and bronchodilators, including Clenbuterol, for all yearlings, and horses in and out of training including Breeze Up two year olds, sold at sales conducted by the two sales houses. The new restrictions will be introduced with effect from the start of the UK and Irish yearling sales season beginning on September 1st with the Goffs UK Premier Yearling Sale and follows consultation with the TBA, ITBA and at the recently formed Bloodstock Industry Forum.
The new Conditions of Sale will allow buyers to have post - sale testing for corticosteroids and bronchodilators (Clenbuterol), with a positive test for undeclared use of corticosteroids, or any trace of bronchodilators (Clenbuterol) resulting in the subject horse being returnable to the vendor at the option of the purchaser under the Conditions of Sale.

The new conditions are in addition to long standing restrictions on the use of anabolic steroids and non - steroidal anti - inflammatories, as well as the ban on the use of Bisphosphonates introduced in 2019.

In a joint statement, Tattersalls Chairman Edmond Mahony and Goffs Group Chief Executive Henry Beeby said:
“Both Tattersalls and Goffs are united in maintaining the highest standards of integrity and horse welfare at all of our sales and the new policies relating to the use of corticosteroids and bronchodilators reflect our shared commitment to addressing issues which threaten in any way to undermine confidence in the marketplace."